Pharmacokinetics of the nitric oxide synthase inhibitor L-N(G)- methylarginine hydrochloride in patients with septic shock

Clinical Pharmacology and Therapeutics

Volumn 65, Issue 1, 1999, Pages 1-9

  Hussein, Ziad ^a,b,c,d,e   Beerahee, Misba ^a,b,c,d   Grover, Robert ^a,b,c,d   Jordan, Bernadette ^a,b,c,d   Jeffs, Roger ^a,b,c,d   Donaldson, Jill ^a,b,c,d   Zaccardelli, David ^a,b,c,d   Colice, Gene ^a,b,c,d   Guntupalli, Kalpalatha ^a,b,c,d   Watson, David ^a,b,c,d   Vincent, Jean Louis ^a,b,c,d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b BEN TAUB GENERAL HOSPITAL   (United States)

^c HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^d ERASME HOSPITAL   (Belgium)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; FEMALE; HEART OUTPUT; HEMODYNAMIC MONITORING; HUMAN; MALE; MEAN ARTERIAL PRESSURE; PATIENT SELECTION; PRIORITY JOURNAL; SEPTIC SHOCK; VASOMOTOR REFLEX;

ADULT; AGED; AREA UNDER CURVE; COHORT STUDIES; ENZYME INHIBITORS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NITRIC OXIDE SYNTHASE; OMEGA-N-METHYLARGININE; SHOCK, SEPTIC;

EID: 0032892009     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(99)70116-5     Document Type: Article

References (35)

1. 1. Glauser MP, Zanetti G, Baumgartner JD, Cohen J. Septic shock: pathogenesis. Lancet 1991;338:732-6.
2. 2. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993;328:1471-7.
3. 3. Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990;113:227-42.
4. 4. Kieft H, Hoepelman AIM, Zhou W, et al. The sepsis syndrome in a Dutch university hospital: clinical observations. Arch Intern Med 1993;153:2241-7.
5. 5. Shoemaker WC, Appel PL, Kram HB, et al. Temporal hemodynamic and oxygen transport patterns in septic shock. Chest 1993;104:1529-36.
6. 6. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993:329:2002-12.
7. 7. Rees DD, Palmer RMJ, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acd Sci USA 1989;86:3375-8.
8. 8. Rees DD, Cellek S, Palmer RMJ, Moncada S. Dexamethasone prevents the induction by endotoxin of nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun 1990;173:541-7.
9. G-methyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun 1990;172:1132-8.
10. G-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 1990;87:3629-32.
11. 11. Kilbourn RG, Griffith OW. Overproduction of nitric oxide in cytokine-mediated septic shock. J Natl Cancer Inst 1992;84:827-31.
12. 12. Ochoa JB, Udekwu AO, Billiar TR, et al. Nitrogen oxide levels in patients after trauma and during sepsis. Ann Surg 1991;214:621-6.
13. 13. Evans T, Carpenter A, Kinderman H, Cohen J. Evidence of increased nitric oxide production in patients with sepsis syndrome. Circ Shock 1993;41:77-81.
14. 14. Shi Y, Li HQ, Shen CK, et al. Plasma nitric oxide levels in newborn infants with sepsis. J Pediatrics 1993;123: 435-8.
15. 15. de Werra I, Jaccard C, Betz Coradin S, et al. Cytokines, nitrite/nitrate, soluble tumour necrosis factor receptors, and procalcitonin concentrations: comparison in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 1997;25:607-13.
16. 16. MacNaul KL, Hutchinson NI. Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions. Biochem Biophys Res Commun 1993;196:1330-4.
17. 17. Palmer RMJ. The discovery of nitric oxide in vessel wall: a unifying concept in pathogenesis of sepsis. Arch Surg 1993;128:396-401.
18. 18. Hecker M, Sessa WC, Harris HJ, et al. The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. Proc Natl Acad Sci USA 1990;87:8612-6.
19. G-methyl-L-arginine functions as an alternate substrate and mechanism-based inhibitor of nitric oxide synthase. Biochemistry 1993;32:9677-85.
20. 20. Schmidt K, Klatt P, Mayer B. Characterisation of endothelial cell amino acid transport systems involved in the actions of nitric oxide synthase inhibitors. Mol Pharmacol 1993;44:615-21.
21. 21. Park KS, Lee HW, Hong SY, et al. Determination of methylated amino acids in human serum by high-performance liquid chromatography. J Chromatogr 1988;440:225-30.
22. 22. Carnegie PR, Fellows FCI, Symington GR. Urinary excretion of methylarginine in human disease. Metabolism 1977;26:531-7.
23. 23. Haynes WG, Noon JP, Walker BR, Webb DJ. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens 1993;11:1375-80.
24. 24. Stamler JJ, Loh E, Rodily MA, et al. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994;89:2035-40.
25. 25. Petros A, Lamb G, Leone A, et al. Effects of nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994;28:34-9.
26. 26. Ogawa T, Kimoto M, Sasoaka K. Dimethylarginine: pyruvate aminotransferase in rats. J Biol Chem 1990;265:20938-45.
27. G-monomethyl-L-arginine. Can J Biochem Cell Biol 1983;61:850-5.
28. G-dimethyl-arginine in the rabbit. Biochem J 1976;154:179-84.
29. 29. MacAllister RJ, Fickling SA, Whitley GSJ, Vallance P. Metabolism of methylarginine by human vasculature: implication for the regulation of nitric oxide synthesis. Br J Pharmacol 1994;112:43-8.
30. 30. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. J Hypertens 1993;11:1375-80.
31. 31. Haynes WG, Hand MF, Dockrell MEC, et al. Physiological role of nitric oxide in regulation of renal function in humans. Am J Physiol 1997;41:364-71.
32. 32. Cooper M, et al. Assay methodology for measuring 546C88 in human plasma and urine. J Chromatogr 1997; 696:117-22.
33. 33. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982.
34. G-methylarginine hydrochloride (546C88) in patients with septic shock. Crit Care Med [in press].
35. G-methyl-arginine hydrochloride) in rat and dog. Xenobiotica 1997;27:1259-71.